Home » Stocks » KURA

Kura Oncology, Inc. (KURA)

Stock Price: $28.59 USD -0.88 (-2.99%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 1.89B
Revenue (ttm) n/a
Net Income (ttm) -89.63M
Shares Out 53.08M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $28.59
Previous Close $29.47
Change ($) -0.88
Change (%) -2.99%
Day's Open 29.85
Day's Range 27.81 - 29.50
Day's Volume 391,723
52-Week Range 9.89 - 43.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC –

3 weeks ago - GlobeNewsWire

The FDA has designated Breakthrough Therapy status to Kura Oncology Inc's (NASDAQ: KURA) tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for head and neck cancer. The status covers ...

1 month ago - Benzinga

– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations –

1 month ago - GlobeNewsWire

SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

1 month ago - GlobeNewsWire

SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

2 months ago - GlobeNewsWire

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

2 months ago - GlobeNewsWire

– Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb – – Panel discussion on precision medicine to be hosted by former FDA Commissioner Dr. Scott Gottlieb –

3 months ago - GlobeNewsWire

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

3 months ago - GlobeNewsWire

SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

4 months ago - GlobeNewsWire

Kura Oncology looks an attractive opportunity in the Precision Medicine / Targeted Therapies sector.

4 months ago - Seeking Alpha

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

4 months ago - GlobeNewsWire

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

4 months ago - GlobeNewsWire

SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

4 months ago - GlobeNewsWire

– Evidence of biologic activity observed in each dose-escalation cohort treated to date –

4 months ago - GlobeNewsWire

Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH

4 months ago - GlobeNewsWire

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of...

5 months ago - GlobeNewsWire

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,...

5 months ago - GlobeNewsWire

– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC –

5 months ago - GlobeNewsWire

– First clinical data from the KOMET-001 study to be presented on December 5, 2020 – – First clinical data from the KOMET-001 study to be presented on December 5, 2020 –

6 months ago - GlobeNewsWire

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

7 months ago - GlobeNewsWire

Kura Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. The post Kura Oncology Clears Key Benchmark, Hitting 90-Plus RS Rating appeared first on Investor's...

7 months ago - Investors Business Daily

Kura Oncology (KURA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance...

7 months ago - GlobeNewsWire

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

8 months ago - GlobeNewsWire

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance...

8 months ago - GlobeNewsWire

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

10 months ago - GlobeNewsWire

– Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma – – Oral presentation to highlight cli...

11 months ago - GlobeNewsWire

SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...

11 months ago - GlobeNewsWire

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...

11 months ago - GlobeNewsWire

SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment o...

11 months ago - GlobeNewsWire

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Kura Oncology is riding the coattails of another clinical-stage biopharmaceutical company.

11 months ago - The Motley Fool

– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients –

1 year ago - GlobeNewsWire

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success –

1 year ago - GlobeNewsWire

Company strengthens leadership team to support pre-commercial efforts and launch optimization Company strengthens leadership team to support pre-commercial efforts and launch optimization

1 year ago - GlobeNewsWire

– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC –

1 year ago - GlobeNewsWire

– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma –

1 year ago - GlobeNewsWire

Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer Study

1 year ago - Seeking Alpha

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – – Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experie...

1 year ago - GlobeNewsWire

– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% –

1 year ago - GlobeNewsWire

– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th –

1 year ago - GlobeNewsWire

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cance...

1 year ago - GlobeNewsWire

– Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness – – Accomplished executive adds extensive experience in launching novel the...

1 year ago - GlobeNewsWire

– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction –

1 year ago - GlobeNewsWire

– Confirmed objective responses achieved in five of 13 evaluable patients –

1 year ago - GlobeNewsWire

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the ... [Read more...]

Industry
Biotechnology
Founded
2014
CEO
Troy Wilson
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
KURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Kura Oncology stock is "Buy." The 12-month stock price forecast is 43.29, which is an increase of 51.42% from the latest price.

Price Target
$43.29
(51.42% upside)
Analyst Consensus: Buy